<DOC>
	<DOCNO>NCT00446524</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability daily administration combination Valsartan Amlodipine 80/5 mg 52 week patient essential hypertension .</brief_summary>
	<brief_title>Long Term Study Valsartan Amlodipine Patients With Essential Hypertension ( Extension Study CVAA489A1301 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<criteria>Patients successfully complete core study ( Study CVAA489A1301 . Patients whose blood pressure Visit 7 Study CVAA489A1301 well control define MSDBP &lt; 90 mmHg MSSBP &lt; 140 mmHg . At investigator 's subinvestigator 's discretion , patient well control ( MSDBP ≥ 90 mmHg MSSBP ≥ 140 mmHg ) , whose MSDBP &lt; 100 mmHg MSSBP &lt; 160 mmHg might participate extension consider acceptable level blood pressure control patient . Male female outpatient . Patients write informed consent participate study . Presence major protocol violation Study CVAA489A1301 . Patients experienced adverse event consider serious drug relate Study CVAA489A1301 . Patients experienced adverse event consider serious drug relate Study CVAA489A1301 . Patients consider unlikely comply requirement specify protocol investigator subinvestigator . Patients gout gouty arthritis . Patients hypersensitive diuretic ( except potassium spar diuretic ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension , Valsartan , Amlodipine , high blood pressure</keyword>
</DOC>